Key result
In patients with first-episode schizophrenia, 48.3% were obese/overweight and 56.5% had dyslipidemia; antipsychotic treatment duration correlated with higher non-HDL-C and triglycerides (P≤0.01).
Why the study?
Does antipsychotic treatment duration and type affect cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders?
Cross-Sectional (n=404)
Yes
Does antipsychotic treatment duration and type affect cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders?
Cardiometabolic risk factors are highly prevalent in patients with first-episode schizophrenia and are associated with both illness duration and early antipsychotic treatment.
No takes yet. Share an insight, caveat, or question.
Early cardiometabolic monitoring is warranted at schizophrenia onset; cross-sectional data leaves open causal effects of antipsychotics.
Correll et al. (2014) conducted a cross-sectional in First-episode schizophrenia spectrum disorders (n=404). Antipsychotic treatment was evaluated on Body composition and fasting lipid, glucose, and insulin parameters. In patients with first-episode schizophrenia, 48.3% were obese/overweight and 56.5% had dyslipidemia; antipsychotic treatment duration correlated with higher non-HDL-C and triglycerides (P≤0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: